Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same

• US 20070009476A1
• Filed: 07/06/2006
• Published: 01/11/2007
• Est. Priority Date: 11/21/2002
• Status: Abandoned Application

• Current Assignee: Charles Wilson, David Epstein, Jeffrey Kurz, Markus Kurz
• Original Assignee: Charles Wilson, David Epstein, Jeffrey Kurz, Markus Kurz
• Inventors: Epstein, David, Wilson, Charles, Kurz, Jeffrey, Kurz, Markus
• Application Number:
  US11/482,671
• Publication Number:
  US 20070009476A1
• Time in Patent Office: Days
• US Class Current: 424/78.270
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/3183 Diol linkers, e.g. glycols or propanediols

Abstract

Materials and methods are provided for producing aptamer therapeutics having improved pharmacokinetic and pharmacodymanic properties, as well as increased target valency. The aptamers produced by the methods of the invention are useful as therapeutics for treating disease.

Claims

1. A high molecular weight aptamer composition comprising:

(a) an aptamer, and (b) two or more polyalkylene glycol (PAG) moieties, wherein said high molecular weight aptamer composition comprises the structure;

5′

-polyalkylene glycol moiety—

aptamer—

polyalkylene moiety-3′

.

2. The aptamer composition of claim 1, wherein each PAG moiety of the high molecular weight aptamer composition independently has a molecular weight selected from the group consisting of approximately 10 kD, approximately 20 kD, and approximately 40 kD.

3. The aptamer composition of claim 2, wherein the 5′

and 3′

PAG moieties of the high molecular weight aptamer composition each comprise polyethylene glycol (PEG).

4. The aptamer composition of claim 1, wherein the aptamer is multi-activated.

5. The aptamer composition of claim 4, wherein the aptamer is bi-activated.

11. A method of treating disease in a subject comprising the steps of administering a therapeutically effective amount of a high molecular weight aptamer composition of claim 1.

12. The aptamer composition of claim 1, wherein the aptamer composition is capable of binding to platelet derived growth factor (PDGF).

13. The aptamer composition of claim 1, wherein the aptamer composition is capable of binding to TGFβ

2.

14. The aptamer composition of claim 1, wherein the high molecular weight aptamer composition has a molecular weight selected from the group consisting of greater than 10 kD, greater than 20 kD, greater than 40 kD and greater than 80 kD.

15. The aptamer composition of claim 2, wherein the high molecular weight aptamer composition has a molecular weight selected from the group consisting of greater than 10 kD, greater than 20 kD, greater than 40 kD and greater than 80 kD.

16. The aptamer composition of claim 1, wherein each PAG moiety of the high molecular weight aptamer composition independently has a molecular weight of approximately 10 kD.

17. The aptamer composition of claim 1, wherein each PAG moiety of the high molecular weight aptamer composition independently has a molecular weight of approximately 20 kD.

18. The aptamer composition of claim 1, wherein each PAG moiety of the high molecular weight aptamer composition independently has a molecular weight of approximately 40 kD.

19. A therapeutic composition comprising the aptamer composition of claim 1.

20. A method of treating disease in a subject comprising administering a therapeutically effective amount of a high molecular weight aptamer composition of claim 1.

6. A method of improving the pharmacokinetic or pharmacodynamic properties of an aptamer therapeutic composition comprising the steps of:

(a) introducing a 5′

reactive group at the 5′

end of a nucleic acid aptamer and a 3′

reactive group at the 3′

end of the aptamer;

(b) reacting the 5′ and

3′

reactive groups on the aptamer with reactive groups on two or more polyalkylene glycol (PAG) stabilizing moieties,

thereby forming a stabilized high molecular weight therapeutic aptamer comprising the structure;

5′

-polyalkylene glycol moiety—

aptamer—

polyalkylene moiety-3′

.

7. The method of claim 6 wherein the 5′

and 3′

reactive groups on the aptamer composition are each an amino group introduced by modified phosphoramidite synthesis.

8. The method of claim 6 wherein the PAG stabilizing moiety is polyethylene glycol (PEG).

9. The method of claim 6 wherein the aptamer is multiply activated.

10. The method of claim 9 wherein the aptamer is bi-activated at 5′

and 3′

termini.